Clinical Trial

Contraceptive Implant Users

Study Description

The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users

A prospective, non-inferiority study to evaluate the pharmacokinetic effect of topiramate on serum Etonogestrel (ENG) levels in contraceptive implant users.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Topiramate

Topiramate - Participants will undergo a 6 week titrated regimen of oral topiramate to reach a maximum dose of 400mg per day: Week 1 - topiramate PO 25mg daily Week 2 - topiramate PO 25mg twice daily Week 3 - topiramate PO 50mg twice daily Week 4 - topiramate PO 100mg twice daily Week 5 - topiramate PO 150mg twice daily Week 6 - topiramate PO 200mg twice daily

Additional Information

Official Study Title

The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users

Clinical Trial ID

NCT03335163

ParticipAid ID

9b6EQa